No Data
No Data
Does Huadong Medicine (SZSE:000963) Have A Healthy Balance Sheet?
Huadong Medicine (000963.SZ): Subsidiary signed an exclusive commercial cooperation agreement for the product.
On August 4th, Gelunhui reported that on August 2nd, 2024, Huadong Medicine (Hangzhou) Co., Ltd., a wholly-owned subsidiary of the company, signed an exclusive commercial cooperation agreement (the "Cooperation Agreement") with Beijing Yimiao Shenzhou Medical Technology Co., Ltd. ("Yimiao Shenzhou"). Huadong Medicine (Hangzhou) obtained the exclusive license to target CD19's autologous CAR-T candidate product IM19 chimeric antigen receptor T cell injection (the "licensed product" or "symbol product") in the mainland China (hereinafter referred to as the "licensed area").
Huadong Medicine (000963.SZ): The domestic marketing application for the injection form of Linasip CAPS has entered the stage of approval supplement.
Huadong Medicine (000963.SZ) stated on the investor interaction platform on July 30 that the domestic listing application for the injection drug Linasip CAPS has entered the supplement phase, and the company is actively promoting the registration of the product.
HK stocks surge | Qunxing Life Sciences-B(02509) rose nearly 9% in the afternoon, reached cooperation with huadong medicine on the development and commercialization of QX005N injection.
In the afternoon, Quanxin Biotechnology-B (02509) rose nearly 9%, as of press time, it rose 7.17%, to HKD 24.65, with a turnover of HKD 2.1469 million.
CHAMPIONSCI(02509) rose 6.97%. Together with huadong medicine, they are conducting clinical and non-clinical research and registration related work on the target product QX005N.
Jingu Finance News | Quanxin Biotechnology (02509) rose more than 8% intraday, and as of press time, it rose 6.97%, to HKD 21.5, with a turnover of HKD 1.86 million. On the news front, the company announced that on July 19, 2024, it had entered into a cooperation agreement with huadong medicine's (000963) wholly-owned subsidiary, Zhongmei Huadong, on the co-development of clinical and non-clinical studies and registration related work for the symbol product QX005N. The announcement stated that if Zhongmei Huadong exercises its option, it will be responsible for the marketing and promotion of the symbol product in the authorized region, while the company will be responsible for the supply and quality of the symbol product and clinical trial samples.
Hong Kong stocks have changed | Qunxin Biotech-B (02509) rose more than 3% and reached a strategic cooperation agreement with Huadong Medicine on QX005N injection.
Quanxin Biotech-B (02509) rose more than 3%, as of press time, up 3.48%, and reported 20.8 Hong Kong dollars, with a turnover of 1.0786 million Hong Kong dollars.
No Data